Summit Therapeutics Inc [SMMT] stock is trading at $19.00, up 1.77%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SMMT shares have gain 2.37% over the last week, with a monthly amount glided 0.05%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Summit Therapeutics Inc [NASDAQ: SMMT] stock has seen the most recent analyst activity on December 11, 2024, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $30. Previously, Jefferies started tracking the stock with Buy rating on December 06, 2024, and set its price target to $31. On November 04, 2024, JMP Securities initiated with a Mkt Outperform rating and assigned a price target of $32 on the stock. Citigroup downgraded its rating to a Neutral and increased its price target to $23 on September 27, 2024. H.C. Wainwright initiated its recommendation with a Buy and recommended $16 as its price target on August 12, 2024. Citigroup started tracking with a Buy rating for this stock on May 07, 2024, and assigned it a price target of $7. In a note dated March 26, 2024, Stifel initiated an Buy rating and provided a target price of $8 on this stock.
Summit Therapeutics Inc [SMMT] stock has fluctuated between $2.10 and $33.89 over the past year. Currently, Wall Street analysts expect the stock to reach $35 within the next 12 months. Summit Therapeutics Inc [NASDAQ: SMMT] shares were valued at $19.00 at the most recent close of the market. An investor can expect a potential return of 84.21% based on the average SMMT price forecast.
Analyzing the SMMT fundamentals
Gross Profit Margin for this corporation currently stands at 3.86% with Operating Profit Margin at 772.26%, Pretax Profit Margin comes in at 837.61%, and Net Profit Margin reading is 836.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.39, Equity is -1.04 and Total Capital is -0.41. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.53 points at the first support level, and at 18.05 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.28, and for the 2nd resistance point, it is at 19.55.
Ratios To Look Out For
For context, Summit Therapeutics Inc’s Current Ratio is 8.31. As well, the Quick Ratio is 8.31, while the Cash Ratio is 1.59.
Transactions by insiders
Recent insider trading involved Zanganeh Mahkam, Chief Executive Officer, that happened on Mar 27 ’24 when 54321.0 shares were purchased. Chief Executive Officer, Zanganeh Mahkam completed a deal on Mar 26 ’24 to buy 30000.0 shares. Meanwhile, Chief Executive Officer Zanganeh Mahkam bought 26000.0 shares on Mar 27 ’24.
